Different from the elevated GRK2 expression, elevated NT‐proBNP38 and ANP39 levels suggest the advanced stage of cardiomyopathy, especially for heart failure; plasma cardiotrophin‐1 expression elevated in diabetes patients with cardiac hypertrophy and systolic dysfunction40; and IGFBP‐7 expression was revealed to be related to insulin resistant, cardiac hypertrophy, and cardiac fibrosis.41 These biomarkers represent several putative mechanistic pathways underlying DCM progression. The gene discussed is GRK2; the disease is cardiac hypertrophy.